We invest our full CRO service stack in early-stage programmes, sharing risk and upside with innovator teams — an R&D partnering platform for young biotechs.
Discuss a partnershipof Team Experience
Monthly Protein Expression Projects
Validated Drug Targets
Target Proteins In Stock
Choose from equity-for-service, in-stock catalog molecule licensing, or targeted development when no molecule is in stock. Testing, rights, and licensing terms are discussed in the tailored partnership proposal.
Shared Risk · Shared Upside
We contribute our full CRO service stack to early-stage pipeline development, advancing the programme with innovator teams while sharing development risk and pipeline upside.
Review the complete validation package for an in-stock catalog molecule, including EC50, internalisation, competition, and endogenous binding; test under an MTA, then complete licensing after the molecule is confirmed.
Jointly define the antigen, immunisation, and screening plan for the target, run phage, yeast, and single-B-cell platforms in parallel, and proceed to buyout licensing after candidate testing.
Off-the-shelf target proteins → antibody screening and optimisation → protein expression → in vitro functional validation — the whole chain runs in-house, with continuous data.
200+ popular-target recombinant proteins in stock across oncology, autoimmune and metabolic disease — no custom lead time, screening and validation start immediately.
Alpaca nanobodies, rabbit monoclonals and human phage-display screening, backed by humanisation and affinity-maturation engineering.
Four platforms — E. coli, Pichia, insect and mammalian cells — for efficient expression at scale.
Core efficacy validation: molecular binding, flow-cytometry binding, reporter-gene activity, neutralisation and TCE killing assays.
Value-added R&D: early ADC molecule screening, antibody developability assessment and physicochemical optimisation.
Under EFS, early-stage cash outlay drops sharply while Sanjing runs the full discovery-to-validation workflow in-house. We share the pipeline's upside, prioritise platform resources toward PCC, and keep terms and exit negotiable.
EFS Equity for Service
Lower cash-flow pressure
One-stop closed loop
Deeply aligned interests
Flexible, customisable deals
Pipeline or target not listed? Share your project background below and we'll assess the fit case by case. See the full target pipeline →
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
